Managing HIV-related cardiomyopathy involves a multidisciplinary approach, combining ART optimization with standard heart failure therapies, including angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and diuretics[16,29,30]. This evidence concerns the gene ACE and cardiomyopathy.